Lorna Moore
Concepts (452)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 86 | 2025 | 473 | 13.740 |
Why?
| | Uterine Artery | 17 | 2024 | 74 | 5.490 |
Why?
| | Fetal Growth Retardation | 35 | 2025 | 591 | 5.240 |
Why?
| | Pre-Eclampsia | 18 | 2025 | 203 | 4.530 |
Why?
| | Hypoxia | 40 | 2025 | 1193 | 4.270 |
Why?
| | Fetal Hypoxia | 12 | 2024 | 56 | 3.800 |
Why?
| | Pregnancy | 79 | 2025 | 7122 | 3.340 |
Why?
| | Acclimatization | 20 | 2019 | 172 | 3.050 |
Why?
| | Uterus | 15 | 2020 | 224 | 3.030 |
Why?
| | Placenta | 18 | 2025 | 781 | 2.870 |
Why?
| | AMP-Activated Protein Kinases | 8 | 2025 | 191 | 2.720 |
Why?
| | Altitude Sickness | 18 | 2022 | 141 | 2.520 |
Why?
| | Fetal Development | 9 | 2024 | 295 | 2.250 |
Why?
| | Placental Circulation | 10 | 2025 | 71 | 2.250 |
Why?
| | Birth Weight | 23 | 2024 | 506 | 2.090 |
Why?
| | Vasodilation | 10 | 2022 | 520 | 1.830 |
Why?
| | Arteries | 10 | 2022 | 258 | 1.830 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2023 | 67 | 1.820 |
Why?
| | Adaptation, Physiological | 13 | 2025 | 567 | 1.720 |
Why?
| | Oxygen | 17 | 2023 | 984 | 1.720 |
Why?
| | Bolivia | 21 | 2025 | 61 | 1.610 |
Why?
| | Biological Evolution | 6 | 2025 | 488 | 1.460 |
Why?
| | Vasoconstriction | 5 | 2015 | 216 | 1.330 |
Why?
| | Regional Blood Flow | 10 | 2024 | 513 | 1.170 |
Why?
| | Middle Cerebral Artery | 2 | 2024 | 56 | 1.030 |
Why?
| | Female | 103 | 2025 | 78304 | 0.990 |
Why?
| | Nitric Oxide Synthase | 4 | 2019 | 234 | 0.980 |
Why?
| | Myometrium | 2 | 2020 | 38 | 0.970 |
Why?
| | Selection, Genetic | 8 | 2019 | 256 | 0.970 |
Why?
| | Fertility | 2 | 2021 | 166 | 0.870 |
Why?
| | Oxygen Consumption | 15 | 2012 | 717 | 0.850 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 949 | 0.850 |
Why?
| | HELLP Syndrome | 1 | 2023 | 5 | 0.810 |
Why?
| | Hemodynamics | 9 | 2024 | 1113 | 0.760 |
Why?
| | Vascular Resistance | 7 | 2024 | 368 | 0.720 |
Why?
| | Tibet | 14 | 2021 | 23 | 0.710 |
Why?
| | Humans | 108 | 2025 | 144667 | 0.710 |
Why?
| | Adult | 60 | 2025 | 40489 | 0.700 |
Why?
| | Pregnancy, Animal | 4 | 2006 | 51 | 0.680 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2019 | 441 | 0.680 |
Why?
| | Infant, Newborn | 23 | 2024 | 6399 | 0.670 |
Why?
| | Gestational Age | 11 | 2024 | 980 | 0.640 |
Why?
| | Hemoglobins | 8 | 2017 | 381 | 0.640 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.620 |
Why?
| | Exercise | 8 | 2018 | 2183 | 0.600 |
Why?
| | Pregnancy Outcome | 4 | 2019 | 479 | 0.600 |
Why?
| | Adrenergic alpha-Antagonists | 4 | 2003 | 34 | 0.600 |
Why?
| | Fetus | 6 | 2025 | 800 | 0.580 |
Why?
| | Polycythemia | 3 | 2017 | 25 | 0.580 |
Why?
| | Maternal-Fetal Exchange | 4 | 2021 | 169 | 0.560 |
Why?
| | Pregnancy Complications | 6 | 2017 | 586 | 0.550 |
Why?
| | Protein Kinases | 1 | 2020 | 314 | 0.550 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.520 |
Why?
| | Catecholamines | 8 | 2003 | 87 | 0.490 |
Why?
| | Women's Health | 2 | 2011 | 307 | 0.470 |
Why?
| | Menstrual Cycle | 7 | 2003 | 140 | 0.460 |
Why?
| | Nitric Oxide | 4 | 2020 | 894 | 0.460 |
Why?
| | Infant, Small for Gestational Age | 3 | 2011 | 111 | 0.450 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 303 | 0.420 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 60 | 0.420 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 429 | 0.420 |
Why?
| | Aromatase | 1 | 2014 | 32 | 0.410 |
Why?
| | Animals | 26 | 2025 | 37948 | 0.410 |
Why?
| | Genetics, Population | 6 | 2010 | 215 | 0.400 |
Why?
| | Blood Pressure | 11 | 2020 | 1766 | 0.390 |
Why?
| | Endothelin-1 | 2 | 2020 | 181 | 0.380 |
Why?
| | Polymorphism, Single Nucleotide | 10 | 2019 | 2137 | 0.380 |
Why?
| | Ultrasonography, Doppler | 3 | 2020 | 126 | 0.370 |
Why?
| | PPAR gamma | 3 | 2020 | 177 | 0.370 |
Why?
| | Indians, South American | 6 | 2015 | 23 | 0.370 |
Why?
| | Phenylephrine | 6 | 2020 | 74 | 0.360 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 75 | 0.360 |
Why?
| | Estrogens | 2 | 2014 | 364 | 0.360 |
Why?
| | Respiratory Mechanics | 4 | 2007 | 73 | 0.360 |
Why?
| | Angiotensin II | 2 | 2011 | 95 | 0.360 |
Why?
| | Guinea Pigs | 8 | 2006 | 160 | 0.350 |
Why?
| | Infant, Low Birth Weight | 2 | 2011 | 154 | 0.350 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 96 | 0.350 |
Why?
| | Gene Frequency | 5 | 2014 | 481 | 0.340 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2011 | 8 | 0.340 |
Why?
| | Enzymes | 1 | 2011 | 65 | 0.340 |
Why?
| | Young Adult | 12 | 2024 | 14122 | 0.340 |
Why?
| | Genome, Human | 4 | 2012 | 420 | 0.340 |
Why?
| | Travel | 1 | 2012 | 136 | 0.340 |
Why?
| | Prazosin | 5 | 2003 | 25 | 0.320 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 4 | 0.320 |
Why?
| | Homeostasis | 2 | 2014 | 639 | 0.320 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 15 | 0.320 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1098 | 0.320 |
Why?
| | South America | 5 | 2017 | 57 | 0.320 |
Why?
| | Infant Mortality | 2 | 2021 | 126 | 0.310 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 74 | 0.300 |
Why?
| | Interleukin-1beta | 1 | 2010 | 390 | 0.280 |
Why?
| | Ultrasonography, Prenatal | 3 | 2024 | 293 | 0.270 |
Why?
| | Antioxidants | 1 | 2011 | 546 | 0.270 |
Why?
| | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2011 | 4 | 0.270 |
Why?
| | Mountaineering | 2 | 2005 | 36 | 0.270 |
Why?
| | Case-Control Studies | 6 | 2024 | 3603 | 0.260 |
Why?
| | Heart Rate | 7 | 2015 | 853 | 0.260 |
Why?
| | Chronic Disease | 9 | 2013 | 1810 | 0.250 |
Why?
| | Europe | 4 | 2009 | 419 | 0.240 |
Why?
| | Blood Flow Velocity | 4 | 2011 | 419 | 0.240 |
Why?
| | Oxidative Stress | 1 | 2013 | 1338 | 0.230 |
Why?
| | Vasoconstrictor Agents | 3 | 2020 | 144 | 0.230 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2005 | 48 | 0.230 |
Why?
| | Acetylcholine | 2 | 2020 | 208 | 0.230 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 81 | 0.220 |
Why?
| | Research | 2 | 2005 | 431 | 0.220 |
Why?
| | Fetal Death | 2 | 2003 | 58 | 0.220 |
Why?
| | Cytokines | 2 | 2010 | 2045 | 0.210 |
Why?
| | Umbilical Arteries | 1 | 2024 | 52 | 0.210 |
Why?
| | Embryonic and Fetal Development | 2 | 2003 | 93 | 0.210 |
Why?
| | Epinephrine | 3 | 2001 | 154 | 0.210 |
Why?
| | Placental Insufficiency | 2 | 2023 | 126 | 0.210 |
Why?
| | Models, Genetic | 2 | 2007 | 531 | 0.210 |
Why?
| | Norepinephrine | 3 | 2001 | 196 | 0.200 |
Why?
| | Mammals | 2 | 2022 | 296 | 0.200 |
Why?
| | Chi-Square Distribution | 2 | 2018 | 524 | 0.200 |
Why?
| | Peru | 2 | 2021 | 62 | 0.200 |
Why?
| | Infant | 6 | 2021 | 10023 | 0.200 |
Why?
| | Parity | 2 | 2018 | 108 | 0.200 |
Why?
| | Mice | 8 | 2021 | 18261 | 0.190 |
Why?
| | Interleukin-6 | 2 | 2010 | 770 | 0.190 |
Why?
| | Mining | 1 | 2003 | 37 | 0.190 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.190 |
Why?
| | Silver | 1 | 2003 | 38 | 0.190 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1046 | 0.190 |
Why?
| | Speech Disorders | 1 | 2002 | 29 | 0.180 |
Why?
| | Receptors, Adrenergic, alpha-1 | 2 | 2001 | 45 | 0.180 |
Why?
| | Fatty Acids | 1 | 2025 | 454 | 0.180 |
Why?
| | Regression Analysis | 3 | 2018 | 998 | 0.180 |
Why?
| | Amino Acids | 3 | 2023 | 521 | 0.180 |
Why?
| | Geography | 3 | 2011 | 203 | 0.180 |
Why?
| | Progesterone | 5 | 2003 | 209 | 0.180 |
Why?
| | Myoglobin | 1 | 2002 | 12 | 0.180 |
Why?
| | Carbohydrate Metabolism | 2 | 2000 | 58 | 0.180 |
Why?
| | Cerebrovascular Circulation | 1 | 2024 | 289 | 0.180 |
Why?
| | Potassium Channels | 2 | 2022 | 145 | 0.180 |
Why?
| | Vasodilator Agents | 2 | 2020 | 329 | 0.180 |
Why?
| | Erythropoiesis | 1 | 2001 | 57 | 0.170 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2003 | 28 | 0.170 |
Why?
| | Motor Skills | 1 | 2002 | 104 | 0.170 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 820 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 2591 | 0.170 |
Why?
| | Reproduction | 1 | 2003 | 207 | 0.170 |
Why?
| | Trophoblasts | 2 | 2019 | 218 | 0.170 |
Why?
| | Developing Countries | 1 | 2023 | 317 | 0.170 |
Why?
| | Luteal Phase | 5 | 2001 | 46 | 0.160 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2020 | 12 | 0.160 |
Why?
| | Signal Transduction | 3 | 2024 | 5185 | 0.160 |
Why?
| | Pyrones | 1 | 2020 | 11 | 0.160 |
Why?
| | Ribonucleotides | 1 | 2020 | 26 | 0.160 |
Why?
| | Muscle Relaxation | 1 | 2000 | 28 | 0.160 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2000 | 35 | 0.160 |
Why?
| | Glycolysis | 2 | 2021 | 341 | 0.160 |
Why?
| | Genotype | 4 | 2014 | 1847 | 0.160 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 138 | 0.150 |
Why?
| | Male | 26 | 2019 | 72431 | 0.150 |
Why?
| | Biphenyl Compounds | 1 | 2020 | 66 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1948 | 0.150 |
Why?
| | Reproductive Health | 1 | 2021 | 90 | 0.150 |
Why?
| | Genetic Markers | 3 | 2012 | 332 | 0.150 |
Why?
| | Thiophenes | 1 | 2020 | 121 | 0.150 |
Why?
| | Arterial Pressure | 2 | 2017 | 133 | 0.150 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 541 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 191 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 251 | 0.150 |
Why?
| | Risk Factors | 5 | 2019 | 10796 | 0.150 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2017 | 21 | 0.150 |
Why?
| | Erythropoietin | 2 | 2017 | 100 | 0.150 |
Why?
| | Blood Volume | 4 | 2007 | 65 | 0.140 |
Why?
| | Biological Transport | 3 | 2019 | 418 | 0.140 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5967 | 0.140 |
Why?
| | Follicular Phase | 5 | 2001 | 38 | 0.140 |
Why?
| | Blood Gas Analysis | 3 | 2007 | 81 | 0.140 |
Why?
| | Glyburide | 1 | 1998 | 31 | 0.140 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 42 | 0.140 |
Why?
| | Analysis of Variance | 3 | 2011 | 1301 | 0.140 |
Why?
| | Maternal Age | 1 | 2018 | 126 | 0.140 |
Why?
| | Estradiol | 5 | 2003 | 507 | 0.140 |
Why?
| | Body Weights and Measures | 2 | 2015 | 37 | 0.140 |
Why?
| | Intraocular Pressure | 1 | 2000 | 326 | 0.140 |
Why?
| | Health Promotion | 1 | 2005 | 771 | 0.140 |
Why?
| | Delivery, Obstetric | 2 | 2011 | 161 | 0.140 |
Why?
| | Sudden Infant Death | 1 | 1998 | 39 | 0.130 |
Why?
| | DNA | 2 | 2006 | 1447 | 0.130 |
Why?
| | Respiration | 3 | 2005 | 206 | 0.130 |
Why?
| | Phenotype | 3 | 2025 | 3147 | 0.130 |
Why?
| | Ethiopia | 1 | 2017 | 44 | 0.130 |
Why?
| | Cohort Studies | 4 | 2020 | 5957 | 0.130 |
Why?
| | Glucose | 2 | 2023 | 1033 | 0.130 |
Why?
| | Physical Endurance | 2 | 2001 | 274 | 0.130 |
Why?
| | Models, Biological | 4 | 2015 | 1811 | 0.130 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 26 | 0.130 |
Why?
| | Vascular Diseases | 2 | 2017 | 252 | 0.130 |
Why?
| | Ovariectomy | 1 | 1997 | 163 | 0.130 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 21 | 0.120 |
Why?
| | Linear Models | 2 | 2014 | 845 | 0.120 |
Why?
| | Pulmonary Gas Exchange | 2 | 2015 | 116 | 0.120 |
Why?
| | Cardiovascular System | 1 | 2017 | 136 | 0.120 |
Why?
| | Time Factors | 8 | 2011 | 7140 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5870 | 0.120 |
Why?
| | Pregnancy Complications, Cardiovascular | 3 | 2007 | 83 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2023 | 550 | 0.110 |
Why?
| | Polymorphism, Genetic | 2 | 2012 | 613 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1537 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 524 | 0.110 |
Why?
| | Electrocardiography | 1 | 1998 | 664 | 0.110 |
Why?
| | Adolescent | 5 | 2019 | 22409 | 0.110 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 203 | 0.110 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 43 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2892 | 0.110 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 48 | 0.100 |
Why?
| | Double-Blind Method | 4 | 2003 | 2033 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2922 | 0.100 |
Why?
| | Body Height | 2 | 2013 | 199 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 641 | 0.100 |
Why?
| | Body Weight | 3 | 2007 | 968 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2022 | 17149 | 0.100 |
Why?
| | Sex Characteristics | 5 | 2001 | 776 | 0.100 |
Why?
| | Atmosphere Exposure Chambers | 2 | 2002 | 7 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 143 | 0.090 |
Why?
| | Hypertension | 3 | 2015 | 1262 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 369 | 0.090 |
Why?
| | Pulmonary Artery | 2 | 2015 | 1124 | 0.090 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2012 | 48 | 0.090 |
Why?
| | Pregnancy Trimesters | 1 | 2012 | 18 | 0.090 |
Why?
| | Optic Atrophy, Hereditary, Leber | 1 | 2012 | 9 | 0.090 |
Why?
| | Indomethacin | 1 | 2012 | 76 | 0.090 |
Why?
| | NADH Dehydrogenase | 1 | 2012 | 20 | 0.090 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2012 | 82 | 0.090 |
Why?
| | Brain | 1 | 2024 | 2934 | 0.090 |
Why?
| | Reference Values | 4 | 2003 | 794 | 0.090 |
Why?
| | Lactic Acid | 3 | 2023 | 303 | 0.090 |
Why?
| | Age Factors | 2 | 2011 | 3329 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 319 | 0.090 |
Why?
| | Polysomnography | 1 | 2013 | 236 | 0.090 |
Why?
| | Colorado | 5 | 2019 | 4558 | 0.090 |
Why?
| | Apgar Score | 1 | 2011 | 20 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2839 | 0.080 |
Why?
| | Atmospheric Pressure | 2 | 2001 | 26 | 0.080 |
Why?
| | Potassium Chloride | 1 | 2011 | 40 | 0.080 |
Why?
| | Nitroarginine | 2 | 2002 | 57 | 0.080 |
Why?
| | Population Dynamics | 1 | 2012 | 158 | 0.080 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 31 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 452 | 0.080 |
Why?
| | Live Birth | 1 | 2011 | 68 | 0.080 |
Why?
| | Iliac Artery | 1 | 2011 | 55 | 0.080 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 212 | 0.080 |
Why?
| | DNA Methylation | 1 | 2015 | 664 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2011 | 331 | 0.080 |
Why?
| | Stillbirth | 1 | 2011 | 79 | 0.080 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 35 | 0.080 |
Why?
| | Child Development | 1 | 2015 | 482 | 0.080 |
Why?
| | Sympathetic Nervous System | 2 | 2003 | 180 | 0.080 |
Why?
| | Alleles | 3 | 2012 | 886 | 0.080 |
Why?
| | Ultrasonography | 1 | 2014 | 776 | 0.080 |
Why?
| | Middle Aged | 5 | 2019 | 35971 | 0.080 |
Why?
| | Haplotypes | 3 | 2017 | 495 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4539 | 0.080 |
Why?
| | Anthropology, Physical | 1 | 2009 | 24 | 0.080 |
Why?
| | Interleukin-4 | 1 | 2010 | 206 | 0.080 |
Why?
| | Mesenteric Arteries | 2 | 2000 | 17 | 0.080 |
Why?
| | Renal Circulation | 3 | 1998 | 75 | 0.070 |
Why?
| | Sheep | 2 | 2023 | 880 | 0.070 |
Why?
| | Genomics | 2 | 2023 | 831 | 0.070 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 253 | 0.070 |
Why?
| | Databases, Genetic | 1 | 2010 | 247 | 0.070 |
Why?
| | Pedigree | 1 | 2010 | 515 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 781 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 848 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 310 | 0.070 |
Why?
| | Ovary | 2 | 2018 | 226 | 0.070 |
Why?
| | Basal Metabolism | 3 | 2003 | 59 | 0.070 |
Why?
| | Exercise Test | 3 | 2001 | 626 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1468 | 0.070 |
Why?
| | Lung | 1 | 2021 | 4089 | 0.060 |
Why?
| | Heart Rate, Fetal | 1 | 2007 | 31 | 0.060 |
Why?
| | Indians, North American | 2 | 2009 | 597 | 0.060 |
Why?
| | Biometry | 1 | 2007 | 66 | 0.060 |
Why?
| | Head | 1 | 2008 | 120 | 0.060 |
Why?
| | Premature Birth | 1 | 2011 | 376 | 0.060 |
Why?
| | Urban Health | 1 | 2007 | 96 | 0.060 |
Why?
| | Prospective Studies | 3 | 2022 | 7994 | 0.060 |
Why?
| | Aorta, Thoracic | 2 | 2000 | 285 | 0.060 |
Why?
| | Femur | 1 | 2008 | 251 | 0.060 |
Why?
| | Health Status | 1 | 2011 | 834 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 507 | 0.060 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2007 | 106 | 0.060 |
Why?
| | Serum | 1 | 2006 | 57 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1207 | 0.060 |
Why?
| | Phylogeny | 2 | 2010 | 1024 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 69 | 0.060 |
Why?
| | Hyperplasia | 1 | 2006 | 177 | 0.060 |
Why?
| | Carnitine | 1 | 2025 | 90 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2350 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 320 | 0.060 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2001 | 18 | 0.060 |
Why?
| | History, 21st Century | 1 | 2005 | 220 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2942 | 0.050 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 177 | 0.050 |
Why?
| | History, 20th Century | 1 | 2005 | 327 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 6041 | 0.050 |
Why?
| | Mental Health | 1 | 2011 | 792 | 0.050 |
Why?
| | Plasma Volume | 1 | 2003 | 20 | 0.050 |
Why?
| | Cardiac Output | 3 | 1998 | 179 | 0.050 |
Why?
| | Child | 4 | 2015 | 22600 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1766 | 0.050 |
Why?
| | Pyruvates | 1 | 2023 | 24 | 0.050 |
Why?
| | Embryo Implantation | 1 | 2003 | 30 | 0.050 |
Why?
| | History, 17th Century | 1 | 2003 | 14 | 0.050 |
Why?
| | Lower Extremity | 1 | 2007 | 440 | 0.050 |
Why?
| | Meclofenamic Acid | 1 | 2002 | 9 | 0.050 |
Why?
| | Acute Disease | 2 | 2005 | 1029 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 294 | 0.050 |
Why?
| | Primary Prevention | 1 | 2005 | 217 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 129 | 0.050 |
Why?
| | Sound Spectrography | 1 | 2002 | 16 | 0.050 |
Why?
| | Glutamine | 1 | 2023 | 108 | 0.050 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 852 | 0.050 |
Why?
| | Speech Acoustics | 1 | 2002 | 12 | 0.050 |
Why?
| | Ischemia | 1 | 2006 | 422 | 0.050 |
Why?
| | Serine | 1 | 2023 | 142 | 0.050 |
Why?
| | Locomotion | 1 | 2003 | 102 | 0.050 |
Why?
| | Muscle Fatigue | 2 | 2001 | 97 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 78 | 0.050 |
Why?
| | Partial Pressure | 1 | 2001 | 30 | 0.040 |
Why?
| | Glycine | 1 | 2023 | 186 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2001 | 25 | 0.040 |
Why?
| | Species Specificity | 1 | 2003 | 573 | 0.040 |
Why?
| | Health Education | 1 | 2005 | 345 | 0.040 |
Why?
| | Cesarean Section | 1 | 2023 | 227 | 0.040 |
Why?
| | Plethysmography | 1 | 2001 | 104 | 0.040 |
Why?
| | Veins | 1 | 2001 | 69 | 0.040 |
Why?
| | Blood Glucose | 3 | 2001 | 2326 | 0.040 |
Why?
| | Pyruvic Acid | 1 | 2021 | 55 | 0.040 |
Why?
| | C-Peptide | 2 | 2001 | 190 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2003 | 342 | 0.040 |
Why?
| | Forearm | 1 | 2001 | 140 | 0.040 |
Why?
| | Ventricular Pressure | 1 | 2021 | 52 | 0.040 |
Why?
| | Arginine | 1 | 2002 | 238 | 0.040 |
Why?
| | Hyperbaric Oxygenation | 1 | 2021 | 39 | 0.040 |
Why?
| | Insulin | 3 | 2001 | 2502 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 985 | 0.040 |
Why?
| | Exons | 1 | 2002 | 362 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2002 | 494 | 0.040 |
Why?
| | Asia | 1 | 2000 | 71 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3729 | 0.040 |
Why?
| | Posture | 1 | 2001 | 197 | 0.040 |
Why?
| | Tonometry, Ocular | 1 | 2000 | 103 | 0.040 |
Why?
| | Bromodeoxyuridine | 1 | 2000 | 77 | 0.040 |
Why?
| | Muscle Contraction | 2 | 2001 | 430 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2001 | 1788 | 0.040 |
Why?
| | Fetal Weight | 1 | 2000 | 53 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 501 | 0.040 |
Why?
| | Paleontology | 1 | 2000 | 20 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2002 | 605 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 27 | 0.040 |
Why?
| | Endothelium | 1 | 2000 | 119 | 0.040 |
Why?
| | Archaeology | 1 | 2000 | 39 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2001 | 239 | 0.040 |
Why?
| | Geographic Mapping | 1 | 2019 | 29 | 0.040 |
Why?
| | North America | 1 | 2000 | 312 | 0.040 |
Why?
| | Organ Size | 1 | 2000 | 461 | 0.040 |
Why?
| | Thiazolidinediones | 1 | 2020 | 139 | 0.040 |
Why?
| | Litter Size | 1 | 1998 | 17 | 0.040 |
Why?
| | Cell Division | 1 | 2000 | 753 | 0.030 |
Why?
| | Potassium Channel Blockers | 1 | 1998 | 47 | 0.030 |
Why?
| | Gene Expression | 1 | 2023 | 1476 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 296 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2006 | 4110 | 0.030 |
Why?
| | Hormones | 1 | 1998 | 133 | 0.030 |
Why?
| | Carotid Sinus | 1 | 1997 | 2 | 0.030 |
Why?
| | Adrenal Glands | 1 | 1998 | 76 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2002 | 575 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 426 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 232 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2019 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1998 | 149 | 0.030 |
Why?
| | Glucagon | 1 | 2018 | 114 | 0.030 |
Why?
| | Genome-Wide Association Study | 2 | 2017 | 1374 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1997 | 50 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1995 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1998 | 422 | 0.030 |
Why?
| | Cats | 1 | 1997 | 228 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 360 | 0.030 |
Why?
| | Glomerular Filtration Rate | 2 | 1998 | 764 | 0.030 |
Why?
| | China | 1 | 1997 | 269 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 70 | 0.030 |
Why?
| | Energy Intake | 1 | 2000 | 501 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 628 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1704 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 11790 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1705 | 0.030 |
Why?
| | California | 1 | 2017 | 471 | 0.030 |
Why?
| | Renin-Angiotensin System | 2 | 2010 | 79 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 835 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 2015 | 104 | 0.030 |
Why?
| | Anesthesia | 1 | 1997 | 258 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2000 | 927 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 572 | 0.020 |
Why?
| | Aged | 2 | 2017 | 25955 | 0.020 |
Why?
| | Latin America | 1 | 2012 | 95 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 303 | 0.020 |
Why?
| | Globins | 1 | 2010 | 21 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 669 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2010 | 27 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1322 | 0.020 |
Why?
| | Thumb | 2 | 2001 | 37 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 184 | 0.020 |
Why?
| | Hydrocortisone | 2 | 2002 | 297 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 828 | 0.020 |
Why?
| | Cyclic GMP | 2 | 1998 | 90 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4312 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2909 | 0.020 |
Why?
| | Indians, Central American | 1 | 2007 | 6 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 41 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5414 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1938 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2007 | 273 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4261 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 751 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8284 | 0.010 |
Why?
| | International Cooperation | 1 | 2005 | 197 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3523 | 0.010 |
Why?
| | Genetic Testing | 1 | 2007 | 480 | 0.010 |
Why?
| | Heart Failure | 1 | 2017 | 2324 | 0.010 |
Why?
| | Tilt-Table Test | 1 | 2001 | 8 | 0.010 |
Why?
| | Placebos | 1 | 2001 | 193 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2001 | 147 | 0.010 |
Why?
| | Societies, Medical | 1 | 2005 | 890 | 0.010 |
Why?
| | Transducers, Pressure | 1 | 1999 | 12 | 0.010 |
Why?
| | Water-Electrolyte Balance | 1 | 2000 | 37 | 0.010 |
Why?
| | Fasting | 1 | 2001 | 275 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 277 | 0.010 |
Why?
| | Electrolytes | 1 | 1998 | 54 | 0.010 |
Why?
| | Nitrogen | 1 | 2000 | 170 | 0.010 |
Why?
| | Pregnancy Trimester, First | 1 | 1998 | 136 | 0.010 |
Why?
| | Renin | 1 | 1997 | 32 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 55 | 0.010 |
Why?
| | Aldosterone | 1 | 1997 | 42 | 0.010 |
Why?
| | Bicarbonates | 1 | 1997 | 45 | 0.010 |
Why?
| | Nitrites | 1 | 1997 | 89 | 0.010 |
Why?
| | Nitrates | 1 | 1997 | 100 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1997 | 205 | 0.010 |
Why?
| | Chlorides | 1 | 1997 | 142 | 0.010 |
Why?
| | Sodium | 1 | 1997 | 198 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 1078 | 0.010 |
Why?
| | Body Composition | 1 | 2000 | 689 | 0.010 |
Why?
| | Poverty | 1 | 1999 | 522 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2001 | 1241 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|